Keyphrases
Thyroid Tumor
81%
Low-density Lipoprotein
68%
Epithelial-mesenchymal Transition
64%
MicroRNA
59%
18F-fluorocholine
57%
Parathyroid Adenoma
57%
Thyroid Carcinoma
57%
Superior Performance
57%
Digital PET
57%
Positron Emission Tomography-computed Tomography (PET-CT)
57%
Aggressiveness
57%
Early Breast Cancer Patients
57%
Circulating microRNA
57%
TPC1
51%
Cholesterol
45%
Breast Cancer
45%
Sentinel Lymph Node
45%
Aggressive Behavior
41%
Gene Expression
41%
Low-density Lipoprotein Receptor
39%
Lymph Node Metastasis
39%
Papillary Thyroid Carcinoma
34%
Transition Process
34%
27-hydroxycholesterol
34%
Thyroid Cancer
34%
Tumor Cells
34%
Tumor Tissue
33%
MiRNA Expression
33%
High-density Lipoprotein Cholesterol (HDL-C)
32%
VATS Thymectomy
28%
Thyroid Carcinoma Cells
28%
Solid Pseudopapillary Tumor
28%
Nuclear Imaging
28%
Nuclear Molecular Imaging
28%
Proteomics
28%
Carcinoma Cell Lines
28%
VDAC2
28%
Inducer
28%
Hyperfunctions
28%
Putative Drug Targets
28%
2D-DIGE
28%
Parathyroid Tissue
28%
Inflammatory Mediators
28%
ABCG2
28%
COVIDSurg
28%
Worldwide Analysis
28%
COVID-19 Impact
28%
Lenvatinib
28%
Regional Metastasis
28%
Anisakiasis
28%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
59%
Fluorine-18
57%
Parathyroid Adenoma
57%
Positron Emission Tomography-Computed Tomography
57%
Thyroid Tumor
57%
microRNA
57%
Low-Density Lipoprotein
57%
Sentinel Lymph Node
36%
LDL Receptor
35%
Metastatic Carcinoma
35%
Tumor Cell
35%
High-Density Lipoprotein
32%
Thymus Surgery
28%
Thyroid Carcinoma
28%
Mesenchymal-Epithelial Transition
28%
Parathyroid
28%
Inflammatory Mediator
28%
Molecular Imaging
28%
Proteomics
28%
Two Dimensional Difference Gel Electrophoresis
28%
Voltage Dependent Anion Channel 2
28%
Solid Pseudopapillary Tumor
28%
Nuclear Medicine
28%
COVID-19
28%
Cross Sectional Study
28%
Circulating microRNA
28%
Estrogen Receptor
28%
Quality of Life
28%
Malignant Neoplasm
28%
down Regulation
27%
Cell Proliferation
26%
Upregulation
19%
Signal Transduction
18%
Mortality Rate
17%
Mitogen-Activated Protein Kinase
15%
Lymph Node
14%
Prostate Cancer
14%
Ovarian Cancer
14%
Homeostasis
14%
Papillary Thyroid Cancer
12%
Gene Expression
11%
Sorafenib
11%
Subgroup Analysis
11%
Biological Marker
11%
Cancer Stem Cell
10%
Cancer Risk
10%
Primary Hyperparathyroidism
9%
Scintigraphy
9%
Disease Duration
9%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Tumor
77%
Breast Cancer
77%
Low Density Lipoprotein
68%
Neoplasm
49%
Thyroid Papillary Carcinoma
46%
Thyroid Cancer
41%
Low Density Lipoprotein Receptor
41%
26 Hydroxycholesterol
35%
Thyroid Carcinoma
31%
Voltage Dependent Anion Channel 2
28%
Solid Pseudopapillary Tumor
28%
ABCG2
28%
Lenvatinib
28%
microRNA
28%
Nanoparticle
28%
Polyglactin
28%
High Density Lipoprotein
28%
Cross-Sectional Study
28%
Epidermal Growth Factor Receptor Antibody
28%
Malignant Neoplasm
28%
Anisakiasis
28%
Ovary Cancer
14%
Prostate Cancer
14%
Low Density Lipoprotein Cholesterol
12%
Lipoprotein
12%
Sorafenib
11%
Disease Duration
9%
Biodistribution
9%
Acute Abdomen
9%
Cancer Survival
9%
Cytotoxicity
9%
Parasitosis
9%
Uvomorulin
8%
Breast Tumor
8%
Antioxidant
7%
High Density Lipoprotein Cholesterol
7%
Scavenger Receptor BI
7%
Clinical Trial
7%
Anti-Inflammatory Drug
7%
Preclinical Study
7%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Pancreas Cancer
7%
Cetuximab
6%
Combination Therapy
6%
Adverse Event
6%
Oxidoreductase
5%
Vimentin
5%
25 Hydroxycholesterol
5%
Endometrium Cancer
5%
Papilloma
5%